1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. ResMed, Inc.
  6. Summary
    RMD   US7611521078

RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  04:00 2022-07-06 pm EDT
217.29 USD   +0.40%
07/01RESMED INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
06/30Resmed Inc. Enters into Second Amended and Restated Credit Agreement
CI
06/30RESMED INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
212.91(c) 209.63(c) 215.72(c) 216.43(c) 217.29(c) Last
478 662 693 647 589 936 504 589 781 977 Volume
+0.78% -1.54% +2.91% +0.33% +0.40% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3 573 M - -
Net income 2022 779 M - -
Net Debt 2022 374 M - -
P/E ratio 2022 41,0x
Yield 2022 0,78%
Sales 2023 4 021 M - -
Net income 2023 926 M - -
Net Debt 2023 187 M - -
P/E ratio 2023 35,1x
Yield 2023 0,85%
Capitalization 31 812 M 31 812 M -
EV / Sales 2022 9,01x
EV / Sales 2023 7,96x
Nbr of Employees 7 970
Free-Float 77,1%
More Financials
Company
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows: - medical devices (50.4%); - masks (37.9%); - software as a service (11.7%). At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China,... 
More about the company
Ratings of ResMed, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about RESMED, INC.
07/01RESMED INC : Change in Directors or Principal Officers, Financial Statements and Exhibits ..
AQ
06/30Resmed Inc. Enters into Second Amended and Restated Credit Agreement
CI
06/30RESMED INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob..
AQ
06/28ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care
GL
06/28ResMed Promotes Lucile Blaise to President, Sleep & Respiratory Care
AQ
06/28ResMed Announces the Promotion of Lucile Blaise to President of Sleep & Respiratory Car..
CI
06/24RESMED INC.(NYSE : RMD) dropped from Russell Midcap Value Index
CI
06/24RESMED INC.(NYSE : RMD) dropped from Russell 1000 Value Index
CI
06/24RESMED INC.(NYSE : RMD) dropped from Russell 3000E Value Index
CI
06/24RESMED INC.(NYSE : RMD) dropped from Russell 3000 Value Index
CI
06/24RESMED INC.(NYSE : RMD) dropped from Russell 1000 Value-Defensive Index
CI
06/24RESMED INC.(NYSE : RMD) added to Russell 1000 Dynamic Index
CI
06/16INSIDER SELL : Resmed
MT
06/15Brokers Divided Over ResMed's SaaS Acquisition
AQ
06/15RBC Lifts Price Target on ResMed to $247 From $244 Amid MEDIFOX DAN Deal, Maintains Out..
MT
More news
News in other languages on RESMED, INC.
06/28ResMed annonce la promotion de Lucile Blaise au poste de présidente de la division Somm..
06/16VENTE D'INITIÉS : Resmed
06/15Les actions australiennes chutent pour la quatrième journée consécutive en raison de la..
06/15ResMed acquiert le fournisseur allemand de logiciels de soins de santé pour 1 milliard ..
06/14USA-Les valeurs à suivre à Wall Street (actualisé)
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 217,29 $
Average target price 243,38 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors